title: Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty.
abstract: The increasing rate of hip fractures is giving rise to a number of socioeconomic problems for the aging community. In addition to being unable to resume their previous living habits, many patients fail to achieve full functional recovery after the fractures. Total hip arthroplasty (THA) is a successful operation for the majority of patients with all forms of hip fractures. Dislocation and aseptic loosening are the major reasons for revisions. An additional problem post-THA is the rate of heterotopic soft tissue calcification after total hip arthroplasty, resulting in severely impaired function, pain, and a reduced range of hip motion. In an open study, 37 women who had undergone cementless total hip arthroplasty after accidental hip fractures were treated twice daily with 200 IU salmon calcitonin nasal spray for 12 months. Simultaneously, the patients received one bag of 1000 mg calcium plus 880 IU vitamin D daily throughout the treatment period of 1 year. A parallel group of 38 women with a similar clinical status in terms of hip fractures and cementless total hip arthroplasty were treated with only one bag of 1000 mg calcium plus 880 IU vitamin D daily through the treatment period. The results of this 12-month clinical trial show that 200 IU salmon calcitonin nasal spray per day promotes general independence from foreign assistance, mobility, and fear of further falls in postmenopausal elderly women following THA. Treatment with a salmon calcitonin nasal spray reduces bone turnover serum markers, loss of further bone density, and pain. Additionally, calcitonin promoted the repair of hip fractures and, as a coincidence finding, was associated with a significantly reduced rate of refractures as well as periprosthetic ossifications.
authors.affiliation: Second Department of Internal Medicine with Rheumatology and Osteology, Kaiser Franz Joseph Hospital, Kundratstrasse 3, A 1100 Vienna, Austria. peter.peichl@wienkav.at
authors.forename: Peter
authors.initials: P
authors.lastname: Peichl
authors.forename: Robert
authors.initials: R
authors.lastname: Marteau
authors.forename: Andrea
authors.initials: A
authors.lastname: Griesmacher
authors.forename: Wofgang
authors.initials: W
authors.lastname: Kumpan
authors.forename: Rudolf
authors.initials: R
authors.lastname: Schedl
authors.forename: Eugen
authors.initials: E
authors.lastname: Prosquil
authors.forename: Paul
authors.initials: P
authors.lastname: Fasol
authors.forename: Hans
authors.initials: H
authors.lastname: Bröll
mesh_terms: D000280:Administration, Inhalation; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip; D015519:Bone Density; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood / Q000652:urine; D005260:Female; D006620:Hip Fractures / Q000601:surgery*; D006801:Humans; D010012:Osteogenesis; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D012008:Recurrence; D016896:Treatment Outcome; D014807:Vitamin D / Q000097:blood / Q000652:urine
chemical_list: D000700:Analgesics; D014807:Vitamin D; C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium